Kestra Medical Technologies (NASDAQ:KMTS) Reaches New 52-Week High – What’s Next?

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) shares reached a new 52-week high during trading on Wednesday. The stock traded as high as $31.99 and last traded at $31.63, with a volume of 519,473 shares trading hands. The stock had previously closed at $29.55.

Analysts Set New Price Targets

Several research analysts have recently weighed in on KMTS shares. Weiss Ratings upgraded shares of Kestra Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, September 16th. BTIG Research reiterated a “buy” rating and issued a $32.00 price target on shares of Kestra Medical Technologies in a report on Tuesday, September 15th. Oppenheimer initiated coverage on Kestra Medical Technologies in a research report on Tuesday, July 21st. They issued a “market perform” rating on the stock. JPMorgan Chase & Co. began coverage on Kestra Medical Technologies in a research note on Monday, August 10th. They set an “overweight” rating and a $30.00 price target for the company. Finally, Wolfe Research set a $30.00 price objective on Kestra Medical Technologies in a report on Wednesday, July 15th. Five equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Kestra Medical Technologies currently has an average rating of “Moderate Buy” and a consensus price target of $29.00.

Kestra Medical Technologies Stock Performance

The company has a current ratio of 4.69, a quick ratio of 4.69 and a debt-to-equity ratio of 0.33. The firm has a market cap of $1.88 billion, a PE ratio of -11.85 and a beta of 0.45. The stock’s 50 day moving average price is $27.13 and its 200 day moving average price is $24.05.

Kestra Medical Technologies (NASDAQ:KMTS) last issued its quarterly earnings data on Monday, September 14th. The company reported ($0.75) EPS for the quarter, missing analysts’ consensus estimates of ($0.61) by ($0.14). Kestra Medical Technologies had a negative return on equity of 63.83% and a negative net margin of 140.43%. The company had revenue of $30.97 million for the quarter. As a group, equities analysts forecast that Kestra Medical Technologies, Ltd. will post -2.45 earnings per share for the current fiscal year.

Insider Activity

In other Kestra Medical Technologies news, insider Brian Webster sold 15,000 shares of the company’s stock in a transaction that occurred on Tuesday, October 20th. The stock was sold at an average price of $29.56, for a total value of $443,400.00. Following the completion of the transaction, the insider owned 445,215 shares in the company, valued at $13,160,555.40. This represents a 3.26% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Elizabeth Kwo sold 4,010 shares of the stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $24.26, for a total transaction of $97,282.60. Following the completion of the sale, the director directly owned 14,116 shares of the company’s stock, valued at $342,454.16. This trade represents a 22.12% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 266,456 shares of company stock worth $7,585,946 in the last ninety days. 5.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the business. Sei Investments Co. increased its holdings in Kestra Medical Technologies by 22.6% during the 1st quarter. Sei Investments Co. now owns 237,116 shares of the company’s stock worth $4,726,000 after purchasing an additional 43,753 shares during the last quarter. The Manufacturers Life Insurance Company increased its stake in shares of Kestra Medical Technologies by 6.6% in the first quarter. The Manufacturers Life Insurance Company now owns 92,515 shares of the company’s stock worth $1,844,000 after buying an additional 5,731 shares during the last quarter. Corient Private Wealth LP raised its holdings in Kestra Medical Technologies by 284.2% in the second quarter. Corient Private Wealth LP now owns 60,614 shares of the company’s stock valued at $1,542,000 after acquiring an additional 44,839 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Kestra Medical Technologies by 47.2% during the 1st quarter. Bank of New York Mellon Corp now owns 70,113 shares of the company’s stock valued at $1,397,000 after acquiring an additional 22,471 shares during the last quarter. Finally, Spartan Wealth Advisory Services LLC bought a new position in Kestra Medical Technologies during the 1st quarter valued at $603,000.

Kestra Medical Technologies Company Profile

Kestra Medical Technologies is a medical technology company focused on wearable solutions for people at risk of sudden cardiac arrest. Its products combine cardiac monitoring, treatment technology and digital services intended to support patients and their care teams. The company’s flagship product, the ASSURE wearable cardioverter defibrillator, continuously monitors a patient’s heart rhythm and can deliver a treatment shock if it detects a life-threatening arrhythmia. The system also provides alerts and supports remote sharing of patient data with clinicians.